Get the Stockscreener App
74.12
0.15%
0.11
After Hours:
74.73
0.61
+0.82%
Sol Gel Technologies Ltd stock is traded at $74.12, with a volume of 21,090.
It is up +0.15% in the last 24 hours and down -4.95% over the past month.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
See More
Previous Close:
$74.01
Open:
$71
24h Volume:
21,090
Relative Volume:
0.52
Market Cap:
$242.30M
Revenue:
$18.47M
Net Income/Loss:
$-1.05M
P/E Ratio:
-210.99
EPS:
-0.3513
Net Cash Flow:
$-33.87M
1W Performance:
-0.39%
1M Performance:
-4.95%
6M Performance:
+61.27%
1Y Performance:
+892.90%
1-Day Range:
$71.00
$77.01
1-Week Range:
$70.85
$77.01
52-Week Range:
$6.96
$97.97
Sol Gel Technologies Ltd Stock (SLGL) Company Profile
Name
Sol Gel Technologies Ltd
Sector
Industry
Phone
-
Address
-
Compare SLGL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLGL
Sol Gel Technologies Ltd
|
74.12 | 242.36M | 18.47M | -1.05M | -33.87M | -0.3513 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sol Gel Technologies Ltd Stock (SLGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Dec-31-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-19 | Reiterated | JMP Securities | Mkt Outperform |
Sol Gel Technologies Ltd Stock (SLGL) Latest News
Sol-Gel Technologies Ltd. Actuals & Estimates (NASDAQ:SLGL) - TradingView
SLGL Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Sol-Gel Technologies Ltd. – NASDAQ:SLGL - TradingView
Enterprise value to revenue forward of Sol-Gel Technologies Ltd. – NASDAQ:SLGL - TradingView
SLGL Initiates Coverage On Mizuho -- Rating Set to Outperform - GuruFocus
Mizuho Securities Initiates Coverage on Sol-Gel With Outperform Rating, $285 Price Target - Moomoo
This Take-Two Interactive Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Mizuho initiates Sol Gel stock with Outperform on BCC therapy potential - Investing.com South Africa
Sol-Gel Technologies Initiated at Outperform by Mizuho - Moomoo
ETFs Investing in Sol-Gel Technologies Ltd. Stocks - TradingView
Sol Gel Technologies Ltd (SLGL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Ordinary Shares of Sol-Gel Technologies Ltd. are subject to a Lock-Up Agreement Ending on 22-JUN-2026. - marketscreener.com
Sol Gel Technologies Ltd (SLGL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sol Gel Technologies Ltd (SLGL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sol Gel Technologies Ltd (SLGL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sol Gel Technologies Ltd (SLGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Sol Gel Technologies Ltd (SLGL) Institutional Confidence - TradingKey
Sol Gel Technologies Ltd (SLGL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sol Gel Technologies Ltd (SLGL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sol Gel Technologies Ltd (SLGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SLGL Q1 2026 Earnings: EPS Surprises to the Upside as Cost Discipline Takes HoldDownward Estimate Revision - newsline.com
Phoenix Financial Ltd. (SLGL) reports 4.99% ownership of Sol‑Gel shares - Stock Titan
Sol-Gel Technologies Ltd. Q1 2026 Earnings: EPS Beat Drives Modest Stock Uptick Despite Continued Pre-Revenue StatusGuidance Update - newsline.com
SLGL Q1 2026 Earnings: Smaller-Than-Expected Loss Drives Stock HigherNext Quarter Guidance - newsline.com
TD Cowen initiates Sol Gel stock with buy on dermatology drug - Investing.com Nigeria
LifeSci Capital Maintains Sol-Gel Technologies(SLGL.US) With Buy Rating, Maintains Target Price $184 - Moomoo
TD Cowen Initiates Sol-Gel Technologies at Buy - Moomoo
Sol Gel Technologies Q1 Loss On US$0.1 Million Revenue Fuels Bearish Narrative - simplywall.st
Sol-Gel Technologies (SLGL) Reports First Quarter Revenue Decline - GuruFocus
Sol Gel Tech earnings beat by $3.15, revenue fell short of estimates - Investing.com Australia
Sol-Gel Technologies Ltd. (SLGL) reports Q1 loss, lags revenue estimates - MSN
Sol-Gel Technologies 1Q EPS $1.31 >SLGL - Moomoo
Sol-Gel Technologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Sol-Gel Technologies Expects Cash Resources to Fund Cash Requirements Into 1Q of 2028 >SLGL - Moomoo
BRIEF-Sol-Gel Technologies Ltd. Q1 Revenue USD 100 Thousand - TradingView
Sol-Gel Technologies (NASDAQ: SLGL) trims Q1 2026 loss and strengthens cash runway - Stock Titan
Sol-Gel wins 2044 patent for Gorlin syndrome gel, raises $33M - Stock Titan
Sol-Gel Q1 2026 earnings: loss narrows as R&D declines - grafa.com
Should I buy SolGel Technologies (SLGL) - Zacks Investment Research
Sol-Gel Technologies (SLGL) Holds Steady Just Below Key Resistance After Modest GainSeasonality Effect - The Legal Advocate
SLGL Q4 2025 Earnings: EPS Misses Estimates as Development-Stage Biotech Reports No RevenueProfit Guidance Range - newsline.com
Sol-Gel Technologies (SLGL) Q4 2025 Earnings: Development-Stage Miss Deepens as Losses Widen; Stock SurgesOperating Income Trends - The Legal Advocate
Opaleye-managed fund buys 1,563 Sol-Gel (SLGL) shares in open market - Stock Titan
SLGL SEC FilingsSol Gel Tech 10-K, 10-Q, 8-K Forms - Stock Titan
Sol-Gel Technologies Surges 4.63% as Shares Test Key Resistance LevelsSocial Trade Signals - Newser
Sol-Gel Technologies Ltd. (SLGL) Q4 2025 Earnings: Wide EPS Miss, Yet Shares ClimbReturn On Capital - Newser
Sol Gel Technologies Ltd Stock (SLGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sol Gel Technologies Ltd Stock (SLGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Jul 01 '26 |
Buy |
71.99 |
312 |
22,461 |
490,312 |
| Opaleye Management Inc. | 10% Owner |
May 20 '26 |
Buy |
64.43 |
1,563 |
100,712 |
490,000 |
| Opaleye Management Inc. | 10% Owner |
May 13 '26 |
Buy |
66.87 |
1,937 |
129,527 |
488,437 |
| Opaleye Management Inc. | 10% Owner |
May 12 '26 |
Buy |
67.98 |
1,500 |
101,975 |
486,500 |
| Opaleye Management Inc. | 10% Owner |
Mar 24 '26 |
Buy |
72.00 |
39,665 |
2,855,880 |
485,000 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):